

Review Form 1.6

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	Ms_JPRI_80868
Title of the Manuscript:	Protocol of Comparative Evaluation of Efficacy of Kulattha Gutika with Atorvastatin in the Management of Dyslipidemia (Medoroga)
Type of the Article	

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

<https://www.journalpri.com/index.php/JPRI/editorial-policy>

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<u>Compulsory</u> REVISION comments	<p>To Find incidence, RCT is not appropriate study design, but Case –Control study has to be done. Findings in the study can be shown as "Prakriti wise distribution".</p> <p>Revise the article with focus on Protocol – novelty, need, salient features, contribution to science and traditional system of medicine. Delete some headings which are not applicable. Give details of AYUVYA software and permission to use it. Modify discussion, conclusion in terms of protocol and its utility, evidence potential, current evidence relevance.</p>	
<u>Minor</u> REVISION comments	<p>Correct grammar and spellings. Objectives have to be relooked as per proposed study design. Prakriti and Dyslipidaemia incidence as proposed is not a proper study design. Case Control studies will be used for Incidence studies. In RCT researcher can find Prakriti wise distribution of Dyslipidaemia. Enclose SoP, as this is a Protocol paper. State Inclusion and exclusion criteria separately. Statistics section has to be modified. Describe data collection, analysis methods. Clearly state about assessments to be done on each follow up.</p>	
<u>Optional/General</u> comments	<p>Kindly state how it is novel from already published study protocols and RCTs on dyslipidaemia? Discuss about compliance measures like patient diary or other monitoring methods</p>	

Review Form 1.6

PART 2:

	Reviewer's comment	Author's comment <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

Reviewer Details:

Name:	Giridhar Vedantam
Department, University & Country	KLE Deemed University, India